Beremagene geperpavec-svdt (Vyjuvek) topical gene therapy for dystrophic epidermolysis bullosa — Coverage Criteria
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Policy governs medical necessity criteria, dosing, site-of-care, and distribution restrictions for beremagene geperpavec-svdt (Vyjuvek) when used to treat wounds in patients with dystrophic epidermolysis bullosa due to COL7A1 mutations; applies to Blue Cross NC members.
Added revenue codes 0891 and 0892 associated with HCPCS code(s).
Expanded pediatric age indication to include from birth and adjusted maximum weekly units per updated FDA labeling.
Removed requirement for absence of serum antibodies to type VII collagen and no evidence of systemic infection; added prohibition on concurrent use with Filsuvez or another gene therapy on same treatment area.
Coverage Criteria
Initial Therapy
Covered when ALL of the following are met
Duration of approval: 180 days (6 months)
Continuation Therapy
Covered when ALL of the following are met
Duration of approval: 365 days (1 year)
Site of Care Criteria
Site of Care allowances and exceptions
Use of the requested agent in combination on the same treatment area with Filsuvez (birch triterpenes) or another gene therapy is explicitly prohibited. Medical record documentation must demonstrate that the treatment will NOT be administered concurrently with Filsuvez or any other gene therapy to the same anatomic treatment area as a condition of approval.
Requests that do not meet the coverage criteria may be considered not medically necessary. Key documentation and eligibility requirements include: confirmed diagnosis of dystrophic epidermolysis bullosa (documentation required) with confirmation by IFM, TEM, or genetic testing showing COL7A1 mutation; at least one cutaneous wound that is clean with adequate granulation tissue, excellent vascularization, and not appearing infected; no current evidence or history of squamous cell carcinoma in the area undergoing treatment; no active infection in the treatment area; prescriber is a specialist or has consulted one; and the requested dose and quantity are within FDA labeled dosing and do not exceed the policy maximum units for the approval period. Failure to document any of these elements may result in denial.
Coding and Dosing
| J3401 | beremagene geperpavec-svdt (Vyjuvek) biological suspension topical |
| 0891 | Special Processed Drugs - FDA Approved Cell Therapy (revenue code) |
| 0892 | Special Processed Drugs - FDA Approved Gene Therapy (revenue code) |
Provider Actions & Requirements
Prior Authorization Required
Prior authorization is required for this therapy. Requests must confirm diagnostic criteria, wound eligibility, absence of squamous cell carcinoma and active infection in the treatment area, specialist involvement or consultation, and that the requested dose and quantity are within FDA‑labeled limits and policy maximums. For inpatient or outpatient hospital administration, Site of Care criteria apply. Approval durations: Initial — 180 days; Continuation — 365 days (when continuation criteria met).
- Affected HCPCS: J3401
- Duration of approval: Initial 180 days; Continuation 365 days
- Site of Care criteria applies for facility administration
Distribution Channel Restriction
Distribution from a specialty pharmacy provider may be required for certain gene and cellular therapies (including beremagene geperpavec-svdt / Vyjuvek) due to cost and distribution channel restrictions. Providers must contact Blue Cross NC to coordinate specialty pharmacy distribution when required.
- Distribution channel restriction: specialty pharmacy distribution may be required
- Coordinate with Blue Cross NC prior to dispensing
Required Documentation
Submit complete medical record documentation with the prior authorization request. Documentation must demonstrate the diagnosis, confirmatory testing, wound characteristics, absence of SCC and infection, specialist involvement, dosing calculations, and any prior approvals or prior therapy history as applicable.
- Diagnosis of dystrophic epidermolysis bullosa (medical record documentation required)
- Confirmatory test: immunofluorescence mapping (IFM), transmission electron microscopy (TEM), or genetic testing showing COL7A1 mutation (medical record documentation required)
- Wound documentation: at least one cutaneous wound that is clean, has adequate granulation tissue, good vascularization, and not clinically infected (describe wound location, size, appearance, and photographs if available)
- Documentation of no current evidence or history of squamous cell carcinoma in the treatment area
- Documentation of no active infection in the treatment area
- Prescriber specialty: treating specialist (dermatologist, geneticist) or documentation of specialist consultation
- Requested dose and quantity details with calculations showing FDA‑labeled dosing and that requested quantity does not exceed policy maximum units (see policy dosing table)
- For facility administration: documentation addressing Site of Care criteria
Documentation‑based Denial Risks
Requests may be denied if the medical record lacks required diagnostic confirmation, wound detail, documentation of absence of SCC or infection, specialist involvement/consultation, or dosing/quantity justification. Incomplete or missing documentation is a common grounds for denial.
- Denial risk if confirmatory testing (IFM, TEM, or genetic testing) is not provided
- Denial risk if wound description, photos, or evidence of cleanliness/granulation/vascularization are missing
- Denial risk if there is insufficient documentation ruling out SCC or active infection in the treatment area
- Denial risk if prescriber specialty or specialist consultation is not documented
- Denial risk if requested dose/quantity exceed FDA labeling or policy maximums without justification
Background
Dystrophic epidermolysis bullosa (DEB) is a genetic blistering disorder caused by mutations in the COL7A1 gene that impair type VII collagen and lead to defective anchoring fibrils at the dermal-epidermal junction. This pathophysiology results in fragile skin and recurrent wounds; beremagene geperpavec-svdt (Vyjuvek) is a topical gene therapy intended to deliver the corrective genetic material to promote wound healing in patients with DEB due to COL7A1 mutations.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.